Breaking News

Vallon Pharmaceuticals Announces Topline Results of its Pivotal SEAL Study for Lead Program, ADAIR, for the Treatment of ADHD

Vallon Prescribed drugs Inc. – Research did not satisfy key endpoint of considerable reduction in Emax Drug Liking for ADAIR vs reference dextroamphetamine, though a craze in favor of ADAIR was observed (p=.16) – All pharmacodynamic secondary endpoints fulfilled with statistical significance Philadelphia, PA, March 21, 2022 (World NEWSWIRE) — Vallon Prescription drugs, Inc. (NASDAQ: […]